ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,725.34
1.91%
US Tech 100
19,439.20
3.08%
Dow Jones
42,086.76
1.41%
Brent Oil
74.18
2.49%
Bitcoin
63,635.53
3.19%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Mineralys Therapeutics Inc (MLYS) Quote

Mineralys Therapeutics Inc

Mineralys Therapeutics Inc (MLYS)

NASDAQ
12.355
0.665
( 5.69% )
Updated: 13:58:49
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
12.355
Bid
12.30
Ask
12.41
Volume
197,816
11.53 Day's Range 12.38
5.85 52 Week Range 16.905
Market Cap
614.373M
Previous Close
11.69
Open
12.04
Last Trade
5800
@
12.355
Last Trade Time
13:58:59
Financial Volume
$ 2,408,786
VWAP
12.1769
Average Volume (3m)
217,181
Shares Outstanding
49,726,675
Dividend Yield
-
PE Ratio
-8.42
Earnings Per Share (EPS)
-1.45
Revenue
-
Net Profit
-71.9M

About Mineralys Therapeutics Inc

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.mineralystx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Mineralys Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MLYS. The last closing price for Mineralys Therapeutics was $11.69. Over the last year, Mineralys Therapeutics shares have traded in a share price range of $ 5.85 to $ 16.905.

Mineralys Therapeutics currently has 49,726,675 shares outstanding. The market capitalization of Mineralys Therapeutics is $581.30 million. Mineralys Therapeutics has a price to earnings ratio (PE ratio) of -8.42.

Ask ADVFN Intelligence (AI)

MLYS Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 13 2024
Edgar (US Regulatory)

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to...

August 13 2024
GlobeNewswire Inc.

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

August 05 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

June 17 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

June 17 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 14 2024
Edgar (US Regulatory)

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

June 14 2024
GlobeNewswire Inc.

Form 8-K - Current report

June 10 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 31 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.7956.8771626297611.5612.44511.412891311.71795416CS
41.25511.306306306311.112.9910.9213222011.90241276CS
121.27511.507220216611.0815.128.5821718112.09821334CS
26-0.315-2.486187845312.6715.128.5818034912.37889967CS
521.35512.31818181821116.9055.8517893111.29014084CS
156-8.745-41.445497630321.121.985.8518786012.84828218CS
260-8.745-41.445497630321.121.985.8518786012.84828218CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GSIWGarden Stage Ltd
$ 5.4287
(139.15%)
48.35M
ZEOZeo Energy Corporation
$ 2.64
(131.58%)
56.07M
TBIOTelesis Bio Inc
$ 2.78
(104.41%)
43.2M
XCURExicure Inc
$ 3.85
(68.12%)
15M
GLMDGalmed Pharmaceuticals Ltd
$ 10.675
(54.71%)
33.46M
HAOHaoxi Health Technology Ltd
$ 0.75
(-75.00%)
6.7M
XCHXCHG Ltd
$ 11.5001
(-37.40%)
1.2M
HOVRNew Horizon Aircraft Ltd
$ 0.49
(-33.87%)
2.75M
PGNYProgyny Inc
$ 16.56
(-32.24%)
11.64M
BLMZBloomZ Inc
$ 0.9601
(-29.92%)
623.63k
NVDANVIDIA Corporation
$ 119.3095
(5.24%)
176.82M
SQQQProShares UltraPro Short QQQ
$ 7.6154
(-9.34%)
154.79M
HOLOMicroCloud Hologram Inc
$ 0.2463
(21.75%)
93.69M
MAXNMaxeon Solar Technologies Ltd
$ 0.1022
(12.43%)
86.5M
FRGTFreight Technologies Inc
$ 0.1211
(-2.26%)
75.14M

Discussion

View Full Feed
Jake731 Jake731 2 minutes ago
Has anyone done any digging in on UI or other under cover companies to see if there’s any movement ?
TPTW
100lbStriper 100lbStriper 2 minutes ago
Stokd $NLST Netlist's Response is due today on Micron's post trial JMOL & New Trial motions in the 294 case won by Netlist. Following is Micron's Reply which is due by Oct 3rd with Netlist's Sur-Reply due by Oct 17th. After that we await Gilstrap's ruling, which presuming is a denial, will start t
NLST
polska polska 3 minutes ago
How does Wall Street feel about spoofing, fomenting, and naked-shorting over several years?
NWBO
toohot toohot 3 minutes ago
I’ll write back to you privately tomorrow afternoon at happy hour.




BUY $BIEL$
BIEL
theorysuit theorysuit 3 minutes ago
They had a 0% ORR in direct, but yeah let's talk about reviving this with ORR endpoint. She thinks the investors forgot about this. This is just pathetic.
NWBO
DewDiligence DewDiligence 3 minutes ago
I can just imagine how the negotiation might have gone, something like the Moe Green/Godfather negotiation, you don't buy me out, I buy you out. Haha!
RVNC
MJAM2020 MJAM2020 3 minutes ago
$FOXO Taking in some volume again today... Green!

imho
mj
FOXO
cableguy cableguy 3 minutes ago
you can try to pump this but dumping Ronn is bringing this down, no bashers needed.


No I differ on that point, for a years time of responsible dilution is necessary for all startups. RONN

Restricted 240,195,896 09/16/2024

Unrestricted 1,121,591
RONN
JettaR JettaR 3 minutes ago
Almost got those. O4's! Or maybe not....
CBDW
Filterthenoise Filterthenoise 3 minutes ago
Where do we go from here diggy? Must be heavy dilution
RNVA
0001 0001 3 minutes ago
dumping started right on schedule
DJT
Lone Clone Lone Clone 4 minutes ago
Sable Receives Multiple Anomalous Cu-Au-Ag Results from the Perk Rocky Project in British Columbia

https://ca.finance.yahoo.com/news/sable-receives-multiple-anomalous-cu-110000140.html

Sable Resources Ltd.
Thu, September 19, 2024 at 4:00 a.m. PDT·13 min read
ArchieK ArchieK 4 minutes ago
Following the fireside chat, a webcast replay will be available via a link on Avid’s investor website at: http://ir.avidbio.com/investor-events.
CDMO
ma snart ma snart 4 minutes ago
58m traded and we haven't dropped tells you we have bottomed reversal imminent
SINC
Tennis Pro Tennis Pro 4 minutes ago
This new “ceo” makes me misss the previous scammer ceo. This new one is just inexperienced and lazy. Not sure how he’s even an employee let alone the ceo.
DRNK
RobotDroid RobotDroid 4 minutes ago
It's been easy money!
NWBO
Its_TradingG Its_TradingG 5 minutes ago
In my opinion, it's becoming evident that Enzolytics Inc. and Adnexus Biotech may be working together in ways that mislead investors, especially given how Chandra is posting multiple Adnexus PRs without addressing details about Enzolytics. Instead of focusing solely on Enzolytics' management (@enzol
ENZC
mineanddine mineanddine 5 minutes ago
Gaurav Chandra’s latest scam CBDW
CBDW
123tom 123tom 5 minutes ago
Bullish looking follow thru bounce today, after holding 5.30 support yesterday. Climbing steps toward the 6's .Let's see
AVXL
Monksdream Monksdream 5 minutes ago
Providing they don’t delist or reverse split
Speaking of reverse splits these are upcoming
https://hedgefollow.com/upcoming-stock-splits.php
I am done I am done 6 minutes ago
$XONI Xtreme Fighting Championships Announces Innovative NIL Partnership with World-Class College Wrestlers and Combat-Sport Veterans
https://finance.yahoo.com/news/xtreme-fighting-championships-announces-innovative-160400010.html
XONI
threewheeler threewheeler 6 minutes ago
AZRH slow and steady workx for me
AZRH
I am done I am done 6 minutes ago
$XONI Xtreme Fighting Championships Announces Innovative NIL Partnership with World-Class College Wrestlers and Combat-Sport Veterans
https://finance.yahoo.com/news/xtreme-fighting-championships-announces-innovative-160400010.html
XONI
cootcat cootcat 6 minutes ago
How much of Swifty does ILUS own? I know Links is major shareholder Swifty. But is it really connected ILUS?
ILUS
JoeMonte1 JoeMonte1 7 minutes ago
Thanks for posting.It will be a great day to see another press release and filings from Falak soon.
PSPW

Your Recent History

NASDAQ
MLYS
Mineralys Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved